scholarly journals Comment on Ramos-Rincon et al. Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study. Medicina 2021, 57, 873

Medicina ◽  
2022 ◽  
Vol 58 (1) ◽  
pp. 82 ◽  
Author(s):  
Robert Geoffrey Twycross ◽  
Aaron Kee Yee Wong ◽  
Bella Vivat

We read with interest the article by Ramos-Rincon and colleagues about patients with COVID-19 dying in acute medical wards in a Spanish University hospital [...]

Medicina ◽  
2021 ◽  
Vol 57 (9) ◽  
pp. 873
Author(s):  
Jose-Manuel Ramos-Rincon ◽  
Oscar Moreno-Perez ◽  
Nazaret Gomez-Martinez ◽  
Manuel Priego-Valladares ◽  
Eduardo Climent-Grana ◽  
...  

Background and Objectives: Descriptions of end-of-life in COVID-19 are limited to small cross-sectional studies. We aimed to assess end-of-life care in inpatients with COVID-19 at Alicante General University Hospital (ALC) and compare differences according to palliative and non-palliative sedation. Material and Methods: This was a retrospective cohort study in inpatients included in the ALC COVID-19 Registry (PCR-RT or antigen-confirmed cases) who died during conventional admission from 1 March to 15 December 2020. We evaluated differences among deceased cases according to administration of palliative sedation. Results: Of 747 patients evaluated, 101 died (13.5%). Sixty-eight (67.3%) died in acute medical wards, and 30 (44.1%) received palliative sedation. The median age of patients with palliative sedation was 85 years; 44% were women, and 30% of cases were nosocomial. Patients with nosocomial acquisition received more palliative sedation than those infected in the community (81.8% [9/11] vs 36.8% [21/57], p = 0.006), and patients admitted with an altered mental state received it less (20% [6/23] vs. 53.3% [24/45], p = 0.032). The median time from admission to starting palliative sedation was 8.5 days (interquartile range [IQR] 3.0–14.5). The main symptoms leading to palliative sedation were dyspnea at rest (90%), pain (60%), and delirium/agitation (36.7%). The median time from palliative sedation to death was 21.8 h (IQR 10.4–41.1). Morphine was used in all palliative sedation perfusions: the main regimen was morphine + hyoscine butyl bromide + midazolam (43.3%). Conclusions: End-of-life palliative sedation in patients with COVID-19 was initiated quite late. Clinicians should anticipate the need for palliative sedation in these patients and recognize the breathlessness, pain, and agitation/delirium that foreshadow death.


Medicina ◽  
2022 ◽  
Vol 58 (1) ◽  
pp. 83
Author(s):  
Jose-Manuel Ramos-Rincon ◽  
Manuel Priego-Valladares

First of all, we want to thank Twycross, Wong, and Vivat [...]


2016 ◽  
Vol 4 (11) ◽  
pp. 1386-1390
Author(s):  
ShereenElazzazy BSc,Pharm,PharmD ◽  
◽  
AzzaHassan MD ◽  
Pascale Haddad ◽  
◽  
...  

Cancer ◽  
2014 ◽  
Vol 120 (10) ◽  
pp. 1572-1578 ◽  
Author(s):  
David Hui ◽  
Neha Didwaniya ◽  
Marieberta Vidal ◽  
Seong Hoon Shin ◽  
Gary Chisholm ◽  
...  

2019 ◽  
Vol 22 (1) ◽  
pp. 71-74 ◽  
Author(s):  
Guilherme D. Carvalho ◽  
Fernanda P. Costa ◽  
João Alberto M. Peruchi ◽  
Geris Mazzutti ◽  
Igor G. Benedetto ◽  
...  

2011 ◽  
Vol 14 (10) ◽  
pp. 1135-1141 ◽  
Author(s):  
Nathalie Bossuyt ◽  
Lieve Van den Block ◽  
Joachim Cohen ◽  
Koen Meeussen ◽  
Johan Bilsen ◽  
...  

2019 ◽  
Vol 22 (3) ◽  
pp. 274-281 ◽  
Author(s):  
Eva Guérin ◽  
Ricardo Batista ◽  
Amy T. Hsu ◽  
Valérie Gratton ◽  
Mathieu Chalifoux ◽  
...  

2017 ◽  
Vol 56 (10) ◽  
pp. 1265-1271 ◽  
Author(s):  
Liisa K. Rautakorpi ◽  
Johanna M. Mäkelä ◽  
Fatemeh Seyednasrollah ◽  
Anna M. Hammais ◽  
Tarja Laitinen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document